Literature DB >> 14709241

Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains.

Eric L Delwart1, Sharyn Orton, Bharat Parekh, Trudy Dobbs, Kenneth Clark, Michael P Busch.   

Abstract

To estimate the prevalence of HIV strains other than the predominant HIV-1B subtype in the U.S. blood donor population we genetically and serologically characterized HIV in infected blood donations collected throughout he United States from 1997 to mid-2000. Using a combination of DNA heteroduplex mobility and DNA sequence analyses of the env and gag regions of HIV-1 we determined that 285 of 312 infections were caused by HIV-1B and six by non-subtype B HIV-1 (four HIV-1C, one HIV-1AE, one HIV-1A). Genetic distances of greater than 14% in the envelope V3-V5 region of the four HIV-1C strains indicated that they did not share a recent common origin. HIV-1 group M, N, and O, and HIV-2 specific peptide serological testing of the 20 PCR-negative samples determined that one infection was caused by HIV-2 and none by HIV-1 group N and O. The major risk factor for infection with a non-HIV-1B strain was sex with an HIV-infected person from Africa although three of seven non-HIV-1B-infected subjects did not fit that category. For four of seven non-HIV-1B-infected subjects the subtype detected was consistent with the African country of origin of the infected person or of their sexual partner. The frequency of genetically confirmed non-subtype-B HIV infection in a geographically dispersed group of infected U.S. blood donors in 1977-2000 was therefore 2.0% (6/312).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14709241     DOI: 10.1089/088922203771881149

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

Authors:  Marine Karchava; Wendy Pulver; Lou Smith; Sean Philpott; Timothy J Sullivan; Judith Wethers; Monica M Parker
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

2.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors.

Authors:  Eric Delwart; Elizabeth Slikas; Susan L Stramer; Hany Kamel; Debra Kessler; David Krysztof; Leslie H Tobler; Danielle M Carrick; Whitney Steele; Deborah Todd; David J Wright; Steven H Kleinman; Michael P Busch
Journal:  J Infect Dis       Date:  2012-01-31       Impact factor: 5.226

Review 4.  The quasispecies nature and biological implications of the hepatitis C virus.

Authors:  Sarah L Fishman; Andrea D Branch
Journal:  Infect Genet Evol       Date:  2009-08-08       Impact factor: 3.342

5.  Seroconverting blood donors as a resource for characterising and optimising recent infection testing algorithms for incidence estimation.

Authors:  Reshma Kassanjee; Alex Welte; Thomas A McWalter; Sheila M Keating; Marion Vermeulen; Susan L Stramer; Michael P Busch
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

6.  Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Authors:  Karen S Slobod; Chris Coleclough; Scott A Brown; John Stambas; Xiaoyan Zhan; Sherri Surman; Bart G Jones; Amy Zirkel; Pamela J Freiden; Brita Brown; Robert Sealy; Mattia Bonsignori; Julia L Hurwitz
Journal:  AIDS Res Ther       Date:  2005-04-28       Impact factor: 2.250

7.  HIV-1 genetic diversity in antenatal cohort, Canada.

Authors:  Bertine S Akouamba; Janique Viel; Hugues Charest; Natacha Merindol; Johanne Samson; Normand Lapointe; Bluma G Brenner; Richard Lalonde; P Richard Harrigan; Marc Boucher; Hugo Soudeyns
Journal:  Emerg Infect Dis       Date:  2005-08       Impact factor: 6.883

8.  HIV-2 diagnosis and quantification in high-risk patients.

Authors:  Philip A Chan; Sarah E Wakeman; Timothy Flanigan; Susan Cu-Uvin; Erna Kojic; Rami Kantor
Journal:  AIDS Res Ther       Date:  2008-08-14       Impact factor: 2.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.